WHAT IS CLAIMED IS:

1. Use of a JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of prurigo nodularis in a subject.

2. The use of claim 1, wherein the JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, is selective for JAK1 over JAK2, JAK3, and Tyk2.

3. The use of claim 1, wherein the JAK1 pathway inhibitor is 4-[3-(cyanomethyl)-3-(3',5'-dimethyl-1H,1'H-4,4'-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, or a pharmaceutically acceptable salt thereof.

4. The use of claim 1, wherein the JAK1 pathway inhibitor is 4-[3-(cyanomethyl)-3-(3',5'-dimethyl-1H,1'H-4,4'-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide phosphoric acid salt.

5. The use of claim 1, wherein the JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

6. The use of claim 1, wherein the JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.

7. The use of any one of claim 1-6, wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is configured to be administered in a daily dose of about 5 mg to about 95 mg on a free base basis.

8. The use of any one of claim 1-6, wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is configured to be administered in a daily dose of about 45 mg or 75 mg on a free base basis.

9. The use of any one of claims 1-8, wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is configured to be administered in combination with a further therapeutic agent.

10. The use of claim 9, wherein the further therapeutic agent is a neurokinin 1 receptor antagonist.

11. The use of claim 10, wherein the neurokinin 1 receptor antagonist is aprepitant.

12. The use of claim 9, wherein the further therapeutic agent is anti-IL-4 / IL-13 antibody.

13. The use of claim 12, wherein the anti-IL-4 / IL-13 antibody is dupilumab, lebrikizumab or tralokinumab.

14. The use of claim 9, wherein the further therapeutic agent is an anti-IL-5 antibody.

15. The use of claim 14, wherein the anti-IL-5 antibody is benralizumab, mepolizumab, or reslizumab.

16. The use of claim 9, wherein the further therapeutic agent is an anti-IL-31 antibody.

17. The use of claim 16, wherein the anti-IL-31 antibody is nemolizumab.

18. The use of any one of claims 1-17, wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is configured to be administered together with at least one pharmaceutically acceptable carrier or excipient.